cannabis_print_logoCannabis Science, Inc. is a development-stage company involved in medical marijuana research and development. The company is committed to creating medicines—both with and without psychoactive properties—that are cannabis-based. These medicines aim to treat both the disease and its symptoms, and are also for general health maintenance. Cannabis Science, Inc. is the first and only publicly traded biotech company in the market that is involved in cannabinoid-based extracts, and trades in the OTC market under the symbol CBIS.

To put it simply, the company’s products are medical cannabinoid formulations that stem from at least one of the cannabinoid compounds of the cannabis plant with a primary focus of treating cancer—one of the most important diseases across the globe.

Formerly known as Gulf Onshore, Inc., Cannabis Science is among the oldest companies in the cannabis industry. From the very beginning, its founders have been dedicated to their cause of nurturing and upholding a spirit that encourages innovation from which novel ideas develop and turn into solutions based on evidence.

Thanks to its unique understanding of metabolic processes, the patent-oriented biotech company aims to provide alternative treatment options for individuals with medical needs that are unmet. The company utilizes an inquiring approach in order to discover and develop therapies that can improve patients’ lives.

Cannabis Science continues to create these products with medical cannabinoid formulations as part of its commitment to advocate for the rights of those dealing with life-threatening and debilitating conditions. It works closely with regulatory agencies on local, national, and international levels to ensure the accessibility of their high-quality cannabinoid pharmaceuticals.

Cannabis Science, Inc. works closely with leading experts in clinical research, drug development, and medicinal characterization to develop, create, and commercialize new therapeutic approaches that treat an extensive number of critical ailments such as infections, cancer, and age-related illnesses. All of the materials used in Cannabis Science’s clinical trial are from cultivation and production facilities that are GMP compliant, and that exceed industry standards and food processing requirements.


Yahoo! Finance: CBIS News

Latest Financial News for CBIS

65 Outstanding Black And Hispanic Men Leading In Cannabis

This article was originally published on The WeedHead’s blog , authored by Dasheeda Dawson. SPOILER ALERT -- You won't find Snoop, Wiz Khalifa or Jay-Z on this list. While researching for the latest update ...

Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth

Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has agreed to go private under sanctions by the U.S. Securities and Exchange Commission (“SEC”). All Cannabis Science shareholders and their shareholdings will remain intact under the same name and entity, Cannabis Science Inc., a Nevada Corporation. Cannabis Science shares will no longer be quoted or traded on any stock market exchange.

Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements

IRVINE, CA, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it is entering a transition stage as trading of the Company’s shares is halted. Cannabis Science will continue to implement its corporate growth strategy and intends to resolve all outstanding regulatory reporting and filing requirements as it goes through its transition. “I can confirm that I found out yesterday that the trading of Cannabis Science’s shares has been halted by regulatory authorities - clearly the paperwork states ‘due to the financials not being filed as a fully-reporting issuer’.  While this is not a favorable situation, we are already addressing this matter directly with the authorities to protect the interests of our shareholders and stakeholders,” states Raymond C. Dabney, President, C.E.O. and Co-Founder of Cannabis Science.

Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions

IRVINE, CA, Aug. 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has signed a joint venture agreement with a Canadian public company, NHS Industries, Ltd. NHS Industries (CSE: (NHS), (NNHHF)). The group will focus on job creation, deliver and develop public and private access educational content, and research various delivery platforms for medical cannabinoid-related products and services, all based on the CBIS Economic Development Plan for Canada, (CBIS/CDN EDP). The new Canadian-based partnership will expand Cannabis Science’s existing operations into Canada through its CDN EDP.

Cannabis Science Prepares Announcements for Revenues and Corporate Growth; Finalizing New Asset Partnerships and Acquisitions Targeting Positive Cash Flow in Key Markets Globally

IRVINE, CA, Aug. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is preparing to announce a number of exciting new partnerships and acquisitions as the Company prepares for a significant growth in revenue and positive cash flow from operations in key markets globally. The Company will be taking corporate actions to fast track this growth, including compiling the Company financials over the next quarter to achieve compliance with its fully reporting status requirements.